Comparison
CJC-1295 vs Ipamorelin
A structural comparison of CJC-1295 and Ipamorelin — two different mechanisms of action on the growth-hormone axis.
CJC-1295 vs Ipamorelin
This page compares the compounds as materials: what class each belongs to, what the molecule looks like, and how each is supplied. It is a structural and analytical reference — it makes no efficacy claims and contains no protocols.
Side-by-side profile
| Property | CJC-1295 | Ipamorelin |
|---|---|---|
| Classification | GHRH analog (with or without DAC) | selective ghrelin receptor (GHS-R) agonist |
| Other designations | — | — |
| Molecular weight | See lot COA | 711.9 g/mol |
| Reported half-life | ~30 min (no-DAC) / ~6–8 days (DAC) | ~2 hours |
| Supplied vial sizes | 5 mg / 10 mg | 5 mg / 10 mg |
| Purity specification | ≥99% HPLC | ≥99% HPLC |
| Research focus | GH-pulse amplitude research | growth-hormone secretagogue research |
Reading the comparison
Receptor classification is the meaningful difference between these compounds; vial size and purity specification are supply characteristics, not properties of the molecule. Where molecular weights differ substantially, expect different reconstitution arithmetic for the same nominal vial mass — run each through the peptide calculator.
Individual references
- CJC-1295
- Ipamorelin
Documentation supplied by PX1 Research
Every PX1 lot ships with HPLC purity, LC-MS identity confirmation, residual solvent, moisture (Karl Fischer), sterility and endotoxin data. Lot records are published at /coa and /endotoxin-reports. Synthesis, purification, lyophilization and vial fill are performed in U.S. facilities — see /manufacturing-process.
Research use only. PX1 Research supplies compounds for laboratory and in-vitro research. Nothing on this page is medical advice, a dosing recommendation, or an offer for human or veterinary use.